Nature Communications (Aug 2022)

Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens

  • Verena Klemis,
  • Tina Schmidt,
  • David Schub,
  • Janine Mihm,
  • Stefanie Marx,
  • Amina Abu-Omar,
  • Laura Ziegler,
  • Franziska Hielscher,
  • Candida Guckelmus,
  • Rebecca Urschel,
  • Stefan Wagenpfeil,
  • Sophie Schneitler,
  • Sören L. Becker,
  • Barbara C. Gärtner,
  • Urban Sester,
  • Martina Sester

DOI
https://doi.org/10.1038/s41467-022-32321-0
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 11

Abstract

Read online

Multiple formulations and technologies for vaccinating against SARS-CoV-2 exist but how the use of these in homologous or heterologous format impacts immunogenicity is far from clear. Here the authors compare a range of heterologous and homologous SARS-CoV-2 vaccination strategies and assess the induced humoral and cellular immune response.